Gourt > Business > Biotechnology and Pharmaceuticals > Associations (4)
Association may refer to:
- Voluntary association, a group of individuals who voluntarily enter into an agreement to accomplish a purpose
- 501(c)(4) organization.
- 501(c) (6) organization.
- Association (statistics), comes from two variables that are related
- Association (psychology), something linked in memory or imagination with a thing or person
- The Association, a pop band
- Archaeological association, in archaeology, the relationship between objects found together
- HMS Association, a Royal Navy ship which sank in 1707
- Association (object-oriented programming), in object-oriented programming, a relationship between classes
- Association (ecology), a set of organisms which appear together and cover areas in a roughly uniform way
- Association (astronomy), combined or co-added group of astronomical exposures
- Professional body
Associació | Assoziation | Asociación | Association | Associazione | Associatie | NGO (曖昧さ回避) | Asocjacja | Ассоциация | NGO | NGO
More on [ Association ]
Pharma Industry / Biotech Industry News From Medical News Today
Phase III Study Showed Rituxan In Combination With Chemotherapy Improved Progression-Free Survival In Patients With Relapsed Chronic Leukemia
Sat, 11 Oct 2008 01:00:00 -0700
Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) today announced that a global Phase III study of Rituxan (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival (PFS), as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia (CLL) compared to chemotherapy alone. There were no new or unexpected safety signals reported in the study.
Early Data Show Potential For Imatinib To Treat Life-threatening Form Of Pulmonary Artery Disease
Sat, 11 Oct 2008 01:00:00 -0700
An early proof-of-concept study presented shows promising results for imatinib in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder.
Boston Scientific To Release Broad Range Of Clinical Trial Data On The Performance Of TAXUS(R) Coronary Stent Systems At TCT 2008
Sat, 11 Oct 2008 00:00:00 -0700
Boston Scientific Corporation (NYSE: BSX) announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, which runs from October 12 to 17 in Washington, D.C.
FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes
Sat, 11 Oct 2008 00:00:00 -0700
Takeda Pharmaceutical Company Limited ("Takeda") announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification that the U.S. Food and Drug Administration (FDA) will not be able to complete its review of the alogliptin New Drug Application (NDA) by the Prescription Drug User Fee Act (PDUFA) date of October 27, 2008.
A Forecast Insight Report Into The Antidiabetics Market - Switching To New Molecule Antidiabetics Drives Market Growth
Fri, 10 Oct 2008 05:00:00 -0700
Research and Markets has announced the addition of the "Forecast Insight: Antidiabetics - Switching to New Molecule Antidiabetics Drives Market Growth" report to their offering. The antidiabetics market is expected to reach $29 billion, across the seven major markets, by 2017.
Izard Nobel LLP Announces Class Action Lawsuit Against Biovail Corporation
Fri, 10 Oct 2008 05:00:00 -0700
The law firm of Izard Nobel LLP, which has significant experience representing investors in prosecuting claims of securities fraud, announces that a lawsuit seeking class action status has been filed in the United States District Court for the Southern District of New York on behalf of those who purchased Biovail Corporation ("Biovail" or the "Company") (NYSE: BVF) between December 14, 2006 and July 19, 2007, inclusive (the "Class Period").
The Seattle Times: Biotech
News on biotechnology pharmaceutical from BioPortfolio.com
Merck Serono Named as a Top Employer by Science Magazine
TickerTech.com:
Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
Interest!ALERT:
Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
Montana's News Station:
The Economist: Biotechnology
Medicine: Shooting down cancer
Thu, 11 Sep 2008 11:04:00 -0000
A theory linking the scourge to stem cells may offer new ways of treating this most terrifying of diseasesEVERY age is afraid of plagues. For the most part, such plagues have been infections. The rich world, though, has brought infectious disease under control and, AIDS aside, the memory dims with every generation. Instead, the fear of disease has transferred itself to cancer. How to prevent it, and how to treat it if prevention has failed, fills the health pages of the newspapers. How this or that celebrity won or lost his or her battle with it seems to fill much of the rest.The military metaphor is not confined to newspapers. It is 37 years since Richard Nixon, then America’s president, declared war on the disease. During that time, the prognosis for cancer patients has got a lot better. Scientists have refined old therapies and found new ones. Moreover, governments have waged a relentless public-health campaign against the biggest cause of cancer—the smoking of tobacco. The war, however, has never looked close to being won. Scan the horizon and there is no sign of a cure. ...
Cancer stem cells: The root of all evil?
Thu, 11 Sep 2008 11:04:00 -0000
Cancer may be caused by stem cells gone bad. If that proves to be correct, it should revolutionise treatmentMUCH of medical research is a hard slog for small reward. But, just occasionally, a finding revolutionises the field and cracks open a whole range of diseases. The discovery in the 19th century that many illnesses are caused by bacteria was one such. The unravelling of Mendelian genetics was another. It now seems likely that medical science is on the brink of a finding of equal significance. The underlying biology of that scourge of modern humanity, cancer, looks as though it is about to yield its main secret. If it does, it is possible that the headline-writer’s cliche, “a cure for cancer”, will come true over the years, just as the antibiotics that followed from the discovery of bacteria swept away previously lethal infectious diseases. The discovery—or, rather, the hypothesis that is now being tested—is that cancers grow from stem cells in the way that healthy organs do. A stem cell is one that, when it divides, produces two unequal daughters. One remains a stem cell while the other multiplies into the sorts of cells required by its organ. This matters for cancer because, at the moment, all the cells of a tumour are seen as more or less equivalent. Therapies designed to kill them do not distinguish between them. Success is defined as eliminating as many of them as possible, so those therapies have been refined to do just that. However, if all that the therapies are doing is killing the descendants of the non-stem-cell daughters, the problem has not been eliminated. Instead of attacking the many, you have to attack the few. That means aiming at the stem cells themselves. ...
Pharmaceuticals: Convergence or conflict?
Thu, 28 Aug 2008 11:35:36 -0000
Drug giants’ recent attempts to buy big biotech firms have provoked a backlashDALLIANCES between conventional pharmaceutical companies and biotechnology firms are nothing new. Big Pharma, eager to refill its emptying drug pipelines, has in recent years looked hopefully to biotech’s upstarts. The drugs giants have pursued all sorts of tie-ups, from alliances to licensing deals to outright purchases of a few smallish companies. But mindful of the sharp cultural differences between the two sorts of firms, they have generally avoided big acquisitions.Until now, that is. In recent weeks Roche, a Swiss pharmaceuticals giant, has made a surprise $44 billion bid for the 44% of Genentech, the world’s biggest biotech firm by stockmarket value, that it does not already own; and Bristol-Myers Squibb (BMS), an American drugs company, has offered $4.5 billion for the 83% of ImClone, an American biotech firm, that it does not already control. These attempts came on the heels of earlier deals in which AstraZeneca, a British drugs giant, bought MedImmune for $15.6 billion, and Takeda of Japan paid $8.8 billion for Millennium. ...
Subscribe to Biotechnology_and_Pharmaceuticals RSS feed 
Phase III Study Showed Rituxan In Combination With Chemotherapy Improved Progression-Free Survival In Patients With Relapsed Chronic Leukemia
Sat, 11 Oct 2008 01:00:00 -0700
Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) today announced that a global Phase III study of Rituxan (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival (PFS), as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia (CLL) compared to chemotherapy alone. There were no new or unexpected safety signals reported in the study.
Early Data Show Potential For Imatinib To Treat Life-threatening Form Of Pulmonary Artery Disease
Sat, 11 Oct 2008 01:00:00 -0700
An early proof-of-concept study presented shows promising results for imatinib in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder.
Boston Scientific To Release Broad Range Of Clinical Trial Data On The Performance Of TAXUS(R) Coronary Stent Systems At TCT 2008
Sat, 11 Oct 2008 00:00:00 -0700
Boston Scientific Corporation (NYSE: BSX) announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, which runs from October 12 to 17 in Washington, D.C.
FDA Continues Review Of Takeda's New Drug Application For Alogliptin (SYR-322), A DPP-4 Agent For Type 2 Diabetes
Sat, 11 Oct 2008 00:00:00 -0700
Takeda Pharmaceutical Company Limited ("Takeda") announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification that the U.S. Food and Drug Administration (FDA) will not be able to complete its review of the alogliptin New Drug Application (NDA) by the Prescription Drug User Fee Act (PDUFA) date of October 27, 2008.
A Forecast Insight Report Into The Antidiabetics Market - Switching To New Molecule Antidiabetics Drives Market Growth
Fri, 10 Oct 2008 05:00:00 -0700
Research and Markets has announced the addition of the "Forecast Insight: Antidiabetics - Switching to New Molecule Antidiabetics Drives Market Growth" report to their offering. The antidiabetics market is expected to reach $29 billion, across the seven major markets, by 2017.
Izard Nobel LLP Announces Class Action Lawsuit Against Biovail Corporation
Fri, 10 Oct 2008 05:00:00 -0700
The law firm of Izard Nobel LLP, which has significant experience representing investors in prosecuting claims of securities fraud, announces that a lawsuit seeking class action status has been filed in the United States District Court for the Southern District of New York on behalf of those who purchased Biovail Corporation ("Biovail" or the "Company") (NYSE: BVF) between December 14, 2006 and July 19, 2007, inclusive (the "Class Period").
The Seattle Times: Biotech
News on biotechnology pharmaceutical from BioPortfolio.com
Merck Serono Named as a Top Employer by Science Magazine
TickerTech.com:
Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
Interest!ALERT:
Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
Montana's News Station:
The Economist: Biotechnology
Medicine: Shooting down cancer
Thu, 11 Sep 2008 11:04:00 -0000
A theory linking the scourge to stem cells may offer new ways of treating this most terrifying of diseasesEVERY age is afraid of plagues. For the most part, such plagues have been infections. The rich world, though, has brought infectious disease under control and, AIDS aside, the memory dims with every generation. Instead, the fear of disease has transferred itself to cancer. How to prevent it, and how to treat it if prevention has failed, fills the health pages of the newspapers. How this or that celebrity won or lost his or her battle with it seems to fill much of the rest.The military metaphor is not confined to newspapers. It is 37 years since Richard Nixon, then America’s president, declared war on the disease. During that time, the prognosis for cancer patients has got a lot better. Scientists have refined old therapies and found new ones. Moreover, governments have waged a relentless public-health campaign against the biggest cause of cancer—the smoking of tobacco. The war, however, has never looked close to being won. Scan the horizon and there is no sign of a cure. ...
Cancer stem cells: The root of all evil?
Thu, 11 Sep 2008 11:04:00 -0000
Cancer may be caused by stem cells gone bad. If that proves to be correct, it should revolutionise treatmentMUCH of medical research is a hard slog for small reward. But, just occasionally, a finding revolutionises the field and cracks open a whole range of diseases. The discovery in the 19th century that many illnesses are caused by bacteria was one such. The unravelling of Mendelian genetics was another. It now seems likely that medical science is on the brink of a finding of equal significance. The underlying biology of that scourge of modern humanity, cancer, looks as though it is about to yield its main secret. If it does, it is possible that the headline-writer’s cliche, “a cure for cancer”, will come true over the years, just as the antibiotics that followed from the discovery of bacteria swept away previously lethal infectious diseases. The discovery—or, rather, the hypothesis that is now being tested—is that cancers grow from stem cells in the way that healthy organs do. A stem cell is one that, when it divides, produces two unequal daughters. One remains a stem cell while the other multiplies into the sorts of cells required by its organ. This matters for cancer because, at the moment, all the cells of a tumour are seen as more or less equivalent. Therapies designed to kill them do not distinguish between them. Success is defined as eliminating as many of them as possible, so those therapies have been refined to do just that. However, if all that the therapies are doing is killing the descendants of the non-stem-cell daughters, the problem has not been eliminated. Instead of attacking the many, you have to attack the few. That means aiming at the stem cells themselves. ...
Pharmaceuticals: Convergence or conflict?
Thu, 28 Aug 2008 11:35:36 -0000
Drug giants’ recent attempts to buy big biotech firms have provoked a backlashDALLIANCES between conventional pharmaceutical companies and biotechnology firms are nothing new. Big Pharma, eager to refill its emptying drug pipelines, has in recent years looked hopefully to biotech’s upstarts. The drugs giants have pursued all sorts of tie-ups, from alliances to licensing deals to outright purchases of a few smallish companies. But mindful of the sharp cultural differences between the two sorts of firms, they have generally avoided big acquisitions.Until now, that is. In recent weeks Roche, a Swiss pharmaceuticals giant, has made a surprise $44 billion bid for the 44% of Genentech, the world’s biggest biotech firm by stockmarket value, that it does not already own; and Bristol-Myers Squibb (BMS), an American drugs company, has offered $4.5 billion for the 83% of ImClone, an American biotech firm, that it does not already control. These attempts came on the heels of earlier deals in which AstraZeneca, a British drugs giant, bought MedImmune for $15.6 billion, and Takeda of Japan paid $8.8 billion for Millennium. ...
| In another night of attacking Barack Obama over his associations, Sean Hannity was confronted about his past relationship ... | |
| Next Video | |
